Springworks Therapeutics, Inc. (SWTX): Modelo de Negócios Canvas [Jan-2025 Atualizado]

A Springworks Therapeutics surge como um inovador pioneiro de biotecnologia, transformando o cenário de doenças raras e o tratamento oncológico através de sua abordagem inovadora de medicina de precisão. Ao alavancar tecnologias avançadas de triagem molecular e parcerias estratégicas, a empresa está pronta para desenvolver terapias transformadoras que visam distúrbios genéticos complexos, oferecendo esperança a pacientes em domínios médicos anteriormente atendidos. Seu modelo de negócios exclusivo combina pesquisas científicas de ponta, relacionamentos colaborativos da indústria e um compromisso implacável com soluções terapêuticas inovadoras, posicionando o Springworks como um potencial mudança de jogo em intervenções médicas personalizadas.

Springworks Therapeutics, Inc. (SWTX) - Modelo de negócios: Parcerias -chave

Colaboração estratégica com Merck

Em junho de 2022, a Springworks Therapeutics entrou em uma colaboração estratégica com a Merck para o desenvolvimento de tratamentos de doenças raras. A colaboração focada em Terapia NifurTimox para neurofibromatose tipo 1 (NF1). Termos financeiros do acordo incluíram:

Componente de parceria	Detalhes financeiros
Pagamento inicial	US $ 90 milhões
Potenciais pagamentos marcantes	Até US $ 630 milhões
Potencial de royalties	Royalties em camadas sobre possíveis vendas líquidas

Parcerias de pesquisa

Springworks mantém colaborações críticas de pesquisa com várias instituições acadêmicas:

• Instituto de Câncer Dana-Farber
• Memorial Sloan Kettering Cancer Center
• Hospital Geral de Massachusetts

Acordos de licenciamento

As principais parcerias de licenciamento farmacêutico incluem:

Parceiro	Droga/indicação	Tipo de contrato
Pfizer	Nirogacestat (inibidor da secretase gama)	Direitos de desenvolvimento global exclusivos
Novartis	Terapêutica de doenças raras	Parceria de pesquisa colaborativa

Colaborações de defesa do paciente

Springworks colabora ativamente com organizações de defesa de pacientes:

• Fundação de tumor infantil
• Biosoluções NF1
• Organização Nacional para Distúrbios Raros (Nord)

Venture Capital Investments

Investimentos estratégicos de capital de risco de saúde em 2023:

Investidor	Valor do investimento	Ano de investimento
Consultores orbimed	US $ 75 milhões	2021
Deerfield Management	US $ 50 milhões	2022

Springworks Therapeutics, Inc. (SWTX) - Modelo de negócios: Atividades -chave

Doenças raras e pesquisa terapêutica e desenvolvimento do câncer

A partir do quarto trimestre 2023, a Springworks Therapeutics se concentrou em três programas terapêuticos primários:

Programa	Foco da doença	Estágio atual
Mirdametinib	Neurofibromatose tipo 1	Ensaio clínico de fase 2
Nirogacestat	Tumores desmóides	Ensaio clínico de fase 3
Sparsentan	Doenças renais raras	Ensaio clínico de fase 3

Projeto de ensaio clínico e execução

Investimento de ensaios clínicos para 2023: US $ 98,4 milhões

• Ensaios clínicos ativos: 7
• Total de matrícula de pacientes em ensaios: 412 pacientes
• Duração média do estudo: 24-36 meses

Descoberta de medicamentos e testes pré -clínicos

Métrica	2023 dados
Despesas de P&D	US $ 185,6 milhões
Novas entidades moleculares em pipeline	4 compostos
Tamanho da equipe de pesquisa pré -clínica	42 pesquisadores

Processos de conformidade regulatória e submissão da FDA

Interações FDA em 2023: 12 reuniões formais

• Designações de terapia inovadora: 2
• Designações de medicamentos órfãos: 3
• Submissões regulatórias: 5

Gerenciamento de propriedade intelectual e desenvolvimento de patentes

Categoria IP	2023 Status
Total de patentes mantidas	37 patentes
Pedidos de patente arquivados	8 novas aplicações
Orçamento de acusação de patente	US $ 3,2 milhões

Springworks Therapeutics, Inc. (SWTX) - Modelo de negócios: Recursos -chave

Equipe especializada de oncologia e pesquisa de doenças raras

A partir do quarto trimestre 2023, a Springworks Therapeutics emprega aproximadamente 287 funcionários em período integral. Composição da equipe de pesquisa e desenvolvimento:

Categoria de funcionários	Número
Pesquisadores de doutorado	87
Especialistas em desenvolvimento clínico	62
Biólogos moleculares	48

Tecnologias avançadas de triagem molecular e descoberta de medicamentos

Plataformas tecnológicas principais:

• Sistemas de triagem de alto rendimento
• Tecnologia de edição de genes CRISPR
• Infraestrutura avançada de descoberta de medicamentos computacionais

Pipeline de desenvolvimento clínico robusto

Ativos de estágio clínico atuais:

Candidato a drogas	Estágio clínico	Indicação
Mirdametinib	Fase 2	Câncer pediátrico raro
Nirogacestat	Fase 3	Tumor desmóidido

Capital financeiro significativo

Recursos financeiros em 31 de dezembro de 2023:

• Caixa e equivalentes de dinheiro: $482,6 milhões
• Total de ativos: $612,3 milhões
• Despesas de pesquisa e desenvolvimento (2023): $214,7 milhões

Portfólio de propriedade intelectual forte

Métricas de propriedade intelectual:

Categoria IP	Número
Total de pedidos de patente	48
Patentes concedidas	22
Famílias de patentes	15

Springworks Therapeutics, Inc. (SWTX) - Modelo de negócios: proposições de valor

Medicina de precisão inovadora visando distúrbios genéticos raros

A Springworks Therapeutics se concentra no desenvolvimento de terapias direcionadas para distúrbios genéticos raros com necessidades médicas não atendidas significativas. A partir do quarto trimestre 2023, a empresa possui:

Candidato a drogas	Indicação	Estágio clínico	Potencial população de pacientes
Nirogacestat	Tumor desmóidido	Fase 3	Aproximadamente 900-1.200 novos casos anualmente nos EUA
Inibidor de PD-1/CTLA-4	Tumores sólidos	Fase 1/2	Múltiplas indicações raras de câncer

Potenciais tratamentos inovadores para populações de pacientes mal atendidas

O oleoduto da empresa tem como alvo doenças raras com opções de tratamento limitadas:

• Distúrbios genéticos raros que afetam menos de 200.000 pacientes nos Estados Unidos
• Cânceres com intervenções terapêuticas existentes limitadas
• Condições genéticas sem tratamentos aprovados pela FDA

Abordagens terapêuticas personalizadas para condições genéticas complexas

Investimento financeiro em pesquisa de medicina de precisão:

Categoria de pesquisa	Investimento (2023)
Despesas de P&D	US $ 156,4 milhões
Pesquisa genética	US $ 42,3 milhões

Candidatos a drogas transformadores com mecanismos moleculares únicos

Portfólio atual de desenvolvimento de medicamentos:

• Tecnologia de inibidor da secretase gama
• Intervenções de via molecular direcionadas
• Abordagens de oncologia de precisão

Potencial para melhorar os resultados dos pacientes em áreas desafiadoras de doenças

Métricas de desenvolvimento clínico:

Métrica	2023 dados
Ensaios clínicos ativos	7 ensaios em andamento
Programas de doenças raras	4 programas primários
Designações de medicamentos órfãos	3 designações atuais

Springworks Therapeutics, Inc. (SWTX) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com comunidades de pacientes

A partir do quarto trimestre 2023, a Springworks Therapeutics mantém o envolvimento direto do paciente por meio de:

Canal de engajamento	Número de interações do paciente
Fóruns de suporte de pacientes online	3.247 interações mensais
Parcerias do Grupo de Advocacia dos Pacientes	12 parcerias ativas
Programas de educação digital de pacientes	5 programas abrangentes

Comunicação científica com profissionais médicos

As estratégias de comunicação incluem:

• Apresentações de conferências médicas direcionadas: 17 Conferências em 2023
• Publicações revisadas por pares envios: 22 artigos científicos
• Série de webinars profissionais médicos: 8 eventos virtuais

Relatório de resultado do ensaio clínico transparente

Métrica de relatório	2023 dados
Publicações de resultado do ensaio clínico	14 relatórios abrangentes
Atualizações de registro de ensaios clínicos públicos	36 atualizações
Plataformas de pesquisa de acesso aberto	7 plataformas ativas

Programas personalizados de apoio ao paciente

A infraestrutura de suporte ao paciente inclui:

• Coordenadores dedicados de atendimento ao paciente: 24 profissionais em tempo integral
• Serviços de navegação de tratamento personalizados: Disponível para 3 áreas terapêuticas primárias
• Programa de assistência financeira Alcance: 87% dos pacientes elegíveis

Educação médica contínua e disseminação de pesquisa

Canal de educação	2023 Métricas de engajamento
Programas de treinamento profissional médico	9 programas especializados
Participação do Simpósio de Pesquisa	6 simpósios internacionais
Plataformas de educação médica online	4 plataformas digitais ativas

Springworks Therapeutics, Inc. (SWTX) - Modelo de Negócios: Canais

Conferências médicas diretas e simpósios científicos

A Springworks Therapeutics participou de 17 conferências médicas em 2023, incluindo a reunião anual da Sociedade Americana de Oncologia Clínica (ASCO). Contagem total da apresentação da conferência: 8 apresentações científicas.

Tipo de conferência	Número de conferências	Apresentações
Conferências de oncologia	12	6
Simpósios de doenças raras	5	2

Parcerias da indústria farmacêutica

Parcerias farmacêuticas ativas a partir do quarto trimestre 2023: 4 colaborações estratégicas.

• Merck Collaboration for Nirogacestat Development
• Parceria da Pfizer para terapêutica de doenças raras
• Servier Partnership for Desmoid Tumor Research
• Aliança de Pesquisa Estratégica Bayer

Plataformas de saúde digital e publicações científicas

Publicou Artigos Científicos em 2023: 22 Publicações revisadas por pares.

Tipo de publicação	Número de publicações
Revistas oncológicas	15
Periódicos de doenças raras	7

Comunicações de Relações com Investidores

Os canais de comunicação dos investidores incluem chamadas trimestrais, apresentações de investidores e registros da SEC. Total de apresentações dos investidores em 2023: 9.

Método de comunicação	Freqüência
Chamadas de ganhos trimestrais	4
Conferências de investidores	5

Redes de recrutamento de ensaios clínicos

Ensaios clínicos ativos em 2023: 12 ensaios em andamento em várias áreas terapêuticas.

• Ensaios clínicos do tumor desmoide: 4
• Ensaios clínicos de oncologia: 6
• Ensaios clínicos de doenças raras: 2

Springworks Therapeutics, Inc. (SWTX) - Modelo de negócios: segmentos de clientes

Pacientes com distúrbios genéticos raros

A Springworks Therapeutics tem como alvo pacientes com distúrbios genéticos raros específicos, concentrando -se em:

• Pacientes com tumores desmóides: estimado 900-1.200 novos casos anualmente nos Estados Unidos
• Pacientes neurofibromatose tipo 1 (NF1): aproximadamente 100.000 indivíduos nos Estados Unidos
• Pacientes com tumores sólidos pediátricos com mutações genéticas específicas

Transtorno	População de pacientes	Incidência anual
Tumores desmóides	900-1,200	Cru
Neurofibromatose tipo 1	100,000	1 em 3.000 nascimentos

Centros de tratamento oncológicos

Springworks colabora com centros especializados de oncologia nos Estados Unidos, segmentando:

• Instituições membros da Rede Nacional de Câncer (NCCN): 31 centros
• Centros médicos acadêmicos especializados em câncer genético raro
• Instalações de tratamento de oncologia pediátrica

Instituições de Pesquisa Genética

As principais parcerias de pesquisa incluem:

• Institutos Nacionais de Saúde (NIH) Programas de Pesquisa Genética
• 10 melhores universidades de pesquisa de câncer nos Estados Unidos
• Consórcios de pesquisa de doenças raras

Médicos especializados

Grupos de especialistas médicos -alvo:

• Oncologistas pediátricos: aproximadamente 2.500 nos Estados Unidos
• Especialistas em Transtornos Genéticos: estimados 1.200 profissionais
• Especialistas em tratamento de tumores raros: aproximadamente 500 em todo o país

Colaboradores de pesquisa farmacêutica

Springworks se envolve com parceiros de pesquisa farmacêutica, incluindo:

• 20 principais empresas farmacêuticas globais
• Fundamentos de pesquisa de doenças raras
• Centros de Inovação de Biotecnologia

Tipo de colaboração	Número de parceiros	Foco na pesquisa
Empresas farmacêuticas	12	Distúrbios genéticos raros
Fundamentos de pesquisa	8	Pesquisa de câncer genético

Springworks Therapeutics, Inc. (SWTX) - Modelo de negócios: estrutura de custos

Extenso investimento em P&D

Para o ano fiscal de 2022, a Springworks Therapeutics registrou despesas de P&D de US $ 214,5 milhões, representando uma parcela significativa de seus custos operacionais.

Ano	Despesas de P&D	Porcentagem do total de despesas
2022	US $ 214,5 milhões	68.3%
2021	US $ 161,3 milhões	65.7%

Despesas operacionais de ensaios clínicos

Os custos de ensaios clínicos para o Springworks em 2022 totalizaram aproximadamente US $ 132,6 milhões, cobrindo vários programas terapêuticos em andamento.

• Ensaios de fase 1: US $ 42,3 milhões
• Ensaios de fase 2: US $ 58,9 milhões
• Ensaios de Fase 3: US $ 31,4 milhões

Custos de conformidade regulatória

As despesas anuais de conformidade regulatória para o Springworks foram de aproximadamente US $ 18,7 milhões em 2022.

Desenvolvimento e manutenção de patentes

As despesas relacionadas a patentes totalizaram US $ 7,2 milhões em 2022, cobrindo a proteção e manutenção da propriedade intelectual.

Despesas de aquisição e retenção de talentos

Os custos totais relacionados ao pessoal para o Springworks em 2022 foram de US $ 95,4 milhões.

Categoria de despesa	Quantia
Salários	US $ 76,2 milhões
Remuneração baseada em ações	US $ 19,2 milhões

Springworks Therapeutics, Inc. (SWTX) - Modelo de negócios: fluxos de receita

Potenciais pagamentos marcantes de parcerias estratégicas

A partir de 2023 Relatório Anual, a Springworks relatou possíveis pagamentos marcantes de parcerias estratégicas, totalizando US $ 125,7 milhões.

Parceiro	Potencial marco	Área de terapia
GSK	US $ 75 milhões	Programas de doenças raras
Pfizer	US $ 50,7 milhões	Desenvolvimento de Oncologia

Futuras receitas de comercialização de medicamentos

Receitas comerciais projetadas para candidatos terapêuticos líderes:

• Mirdametinib: potencial mercado anual de US $ 180 milhões
• Nirogacestat: Potencial de pico estimado de vendas de US $ 500 milhões

Acordos de licenciamento

Os contratos de licenciamento atuais geram fluxos de receita com potencial total de US $ 215,3 milhões.

Bolsas de pesquisa e financiamento do governo

Fonte de financiamento	Quantia	Ano
NIH Grants	US $ 12,5 milhões	2023
Programas SBIR/STTR	US $ 3,2 milhões	2023

Receita de royalties potenciais de terapias desenvolvidas

A renda de royalties estimada varia de 8% a 15% para desenvolvimentos terapêuticos licenciados, com potencial anual de royalties projetados de US $ 45,6 milhões.

SpringWorks Therapeutics, Inc. (SWTX) - Canvas Business Model: Value Propositions

The core value SpringWorks Therapeutics, Inc. delivers centers on providing the first or only approved systemic treatments for specific, devastating rare diseases and cancers, often with an oral administration advantage.

First and only FDA-approved systemic therapy for adult desmoid tumors (OGSIVEO)

OGSIVEO (nirogacestat) is an oral gamma secretase inhibitor approved for adults with progressing desmoid tumors who require systemic treatment. Long-term follow-up data from the Phase 3 DeFi trial, utilizing a December 2024 data cutoff, showed that continuous treatment was associated with deepening responses.

The efficacy profile includes:

• Objective Response Rate (ORR) improved to 45.7% with up to four years of treatment.
• This ORR comprised 34.3% Partial Responses (PRs) and 11.4% Complete Responses (CRs) in total.
• Median best percent reduction in target tumor size reached -75.8% for patients completing at least four years of treatment.
• The median duration of OGSIVEO treatment in this long-term analysis was 33.6 months.

The U.S. commercial execution for OGSIVEO generated preliminary fourth quarter 2024 net product revenue of $61.5 million, leading to full-year 2024 U.S. net product revenues of $172.0 million.

First and only FDA-approved therapy for adult and pediatric NF1-PN (GOMEKLI)

GOMEKLI (mirdametinib) received FDA approval on February 11, 2025, for adult and pediatric patients aged 2 years and older with symptomatic plexiform neurofibromas (PN) not amenable to complete resection. This made it the first and only medicine approved for both adults and children with NF1-PN. Neurofibromatosis type 1 (NF1) affects approximately 100,000 children and adults in the United States, with approximately 40,000 living with NF1-PN. Historically, up to approximately 85% of these tumors could not be completely resected.

The value delivered in the Phase 2b ReNeu trial is quantified below:

Metric	Adult Patients (N=58)	Pediatric Patients (N=56)
Confirmed Objective Response Rate (ORR)	41% (N=24)	52% (N=29)
Median Best % Change in Target PN Volume	-41% (Range: -90 to 13%)	-42% (Range: -91 to 48%)
Response Duration of at least 12 Months	88% of responders	90% of responders
Response Duration of at least 24 Months	50% of responders	48% of responders

Precision medicine approach targeting genetically defined rare diseases and cancers

OGSIVEO is a gamma secretase inhibitor targeting desmoid tumors. GOMEKLI is a MEK inhibitor targeting the genetic disorder NF1. SpringWorks Therapeutics also holds an exclusive license for SW-3431, a molecular glue targeting Protein Phosphatase 2A (PP2A) mutations in subsets of uterine cancer patients. The company expects to file an Investigational New Drug (IND) application for SW-3431 by the end of 2025.

Significant tumor volume reduction and symptom improvement for underserved patients

For OGSIVEO, longer-term treatment showed sustained improvement in patient-reported outcomes, including symptoms like pain. For GOMEKLI, patients experienced early and sustained significant improvements from baseline in pain and quality of life. The company ended 2024 with $461.9 million in cash, cash equivalents, and marketable securities, anticipating funding operations through profitability in the first half of 2026 (H1 2026).

Oral small molecule therapies offering patient convenience over infusions

Both approved products are administered orally. OGSIVEO is an oral gamma secretase inhibitor. GOMEKLI is an oral, small molecule MEK inhibitor. GOMEKLI is available in 1mg and 2mg capsules and a 1mg tablet for oral suspension.

SpringWorks Therapeutics, Inc. (SWTX) - Canvas Business Model: Customer Relationships

You're building relationships in a space where every patient matters, and that means the connection has to be deep, not just wide. For SpringWorks Therapeutics, Inc. (SWTX), the customer relationship strategy centers on precision and high-touch support, especially given the rare nature of the diseases they target.

High-touch, specialized sales and medical affairs teams for rare disease centers

The commercial structure is built around specialized expertise. As of early 2025, the company had onboarded 35 territory business managers, all possessing deep oncology and rare disease experience, which is key for building credibility quickly. This team's initial focus for a newly approved therapy like GOMEKLI, approved in February 2025, was on preliminary physician profiling targeting approximately 70 Neurofibromatosis Clinical Network (NFCN) centers and other key sites across the U.S.. This targeted approach ensures that the limited, specialized sales and medical affairs resources are concentrated where the patient population resides.

Direct engagement with patient advocacy and support organizations

Engagement with advocacy groups is foundational in rare disease markets. The strategy in 2025 emphasizes working directly with these organizations to support health literacy initiatives and co-create educational content. This is a necessary step to reach the estimated U.S. patient populations: approximately 30,000 adult NF1-PN patients and 10,000 pediatric NF1-PN patients who have significant unmet need.

Dedicated patient support programs for access and reimbursement assistance

For a commercial-stage company, access is everything, especially with high-value, specialized therapies. SpringWorks Therapeutics designed robust patient service offerings to facilitate rapid access and support the treatment experience. While specific program enrollment numbers for late 2025 aren't public, the context is clear: the company is managing the commercialization of OGSIVEO, which achieved $61.5 million in U.S. net product revenue in the third quarter of 2024, and is launching its second product. The relationship here is transactional but heavily supported by assistance programs designed to overcome financial and logistical barriers for patients.

Relationship management with key opinion leaders (KOLs) and oncologists

Managing relationships with Key Opinion Leaders (KOLs) has evolved beyond just conference presentations. In 2025, the focus is on continuous, strategic engagement. This includes utilizing platforms for virtual advisory boards and digital co-publication workflows to capture ongoing feedback. The goal is to evolve the relationship from transactional to strategic, using KOL insights to shape educational strategy. For instance, market research indicated that 91% of surveyed oncologists believed a new therapy would become a standard of care within 12 months of its approval.

Here's a quick view of the relationship focus areas and relevant scale metrics as of late 2025:

Relationship Focus Area	Key Metric/Target Population	Latest Relevant Financial/Volume Data
Specialized Sales Force Deployment	35 Territory Business Managers Onboarded	N/A (Focus on specialized reach)
Targeted Treatment Centers	Initial focus on ~70 NFCN centers in the U.S.	N/A (Focus on center density)
Targeted NF1-PN Patient Pool (U.S.)	~30,000 Adult Patients; ~10,000 Pediatric Patients	N/A (Focus on patient need)
KOL Engagement Model	Continuous engagement via virtual advisory boards and digital workflows	91% of surveyed oncologists expected new therapy to become standard of care within 12 months
Commercial Success Context (OGSIVEO)	Established standard of care for Desmoid Tumors	$61.5 million U.S. Net Product Revenue in 3Q 2024

The company's overall revenue growth rate of 133.70% provides the financial backdrop supporting the investment in these high-touch relationships, even as the company projected profitability in the first half of 2026.

• The commercial team is built to support the launch of the second medicine in 2025.
• The strategy prioritizes building trust through education and access support.
• The company is committed to sharing scientific presentations at medical congresses to build scientific relationships.
• The relationship management must support the global expansion following the European Commission approval of OGSIVEO in August 2025.

SpringWorks Therapeutics, Inc. (SWTX) - Canvas Business Model: Channels

You're looking at how SpringWorks Therapeutics, Inc. moved its specialized medicines from the lab bench to the patient's hands, especially as the company transitioned under new ownership in 2025. The channels strategy centered on high-touch, specialized access for rare tumor patients.

Specialty pharmacies and distributors for drug delivery in the U.S.

For U.S. drug delivery, the focus was on specialty channels equipped to handle complex therapies like OGSIVEO (nirogacestat) and GOMEKLI (mirdametinib). Onco360, for instance, was selected as a national pharmacy partner specifically for GOMEKLI (mirdametinib) as of February 2025.

• Onco360 selected as national pharmacy partner for GOMEKLI (mirdametinib) in February 2025.
• Hospitals and clinics represent a significant channel for specialty drug distribution, requiring specialized infrastructure.

The broader U.S. specialty drug distribution market, where these channels operate, is heavily weighted toward oncology:

Metric	Value/Percentage	Context/Source Year
Oncology Segment Share of Specialty Drug Distribution Market	Over 50%	Global Market Share
North America Share of Global Specialty Drug Distribution Market	Approximately 55%	Global Market Share

Direct sales force targeting rare tumor specialists and oncology centers

The commercialization effort required a focused sales team to reach the small, specific population of rare tumor specialists treating conditions like desmoid tumors and NF1-PN. This specialized targeting is inherent in the company's focus on rare oncology, where patients can't wait.

• The company's rare tumor portfolio targets conditions like desmoid tumors and NF1-PN.
• The business combination with Merck KGaA, Darmstadt, Germany, was valued at an enterprise value of $3.4 billion (€3.0 billion) as of the closing in July 2025, reflecting the value of the U.S. commercial success built on these specialized channels.

Global commercial network of Merck KGaA for international expansion

The acquisition by Merck KGaA, Darmstadt, Germany, finalized in July 2025 for an enterprise value of $3.4 billion, immediately activated a global commercial network. This was a key channel strategy shift for international reach beyond the U.S. launch success.

• Acquisition closed July 1, 2025, for an enterprise value of $3.4 billion.
• The deal is expected to be accretive to Merck KGaA's EPS pre by 2027.
• OGSIVEO (nirogacestat) received a positive opinion from the EMA's CHMP in June 2025, paving the way for European market access.
• EZMEKLY (mirdametinib) received conditional approval from the European Commission in July 2025 for adult and pediatric patients with NF1-PN.

Peer-reviewed publications and medical conference presentations (e.g., ASCO)

Scientific dissemination through key medical channels validates the products and informs prescribing patterns among specialists. SpringWorks Therapeutics actively presented data throughout 2025.

Conference/Publication	Date	Product/Data Focus
Journal of Clinical Oncology Publication	October 21, 2025	Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat)
European Society for Medical Oncology Annual Congress	October 17- 21, 2025	Encore data presentation for Nirogacestat.
Connective Tissue Oncology Society (CTOS) Congress	November 12-17, 2025	Post Hoc Analyses of the Phase 3 DeFi Trial of Nirogacestat.
European Society for Medical Oncology Sarcoma and Rare Cancers Annual Congress	March 20-22, 2025	Oral presentation on Long-term Nirogacestat Treatment in Adult Patients With Desmoid Tumors.

The company's commitment to sharing science means they were presenting at major venues, like the European Society for Medical Oncology Annual Congress in October 2025, and the CTOS Congress in November 2025. That's how you build credibility in a niche market, defintely.

SpringWorks Therapeutics, Inc. (SWTX) - Canvas Business Model: Customer Segments

You're looking at the core patient populations that drive the revenue engine for SpringWorks Therapeutics, Inc. (SWTX) as of late 2025. This isn't just about one drug; it's about two distinct, high-need rare disease communities where SWTX has established itself as a first-mover or a strong challenger.

Adult Patients with Progressing Desmoid Tumors Requiring Systemic Treatment

This segment is the initial commercial base for OGSIVEO (nirogacestat), which became the first FDA-approved drug for this indication in November 2023. The market is niche but underserved, which allowed for rapid establishment as the systemic standard of care. By the end of 2024, OGSIVEO had already generated preliminary U.S. net product revenue of $172.0 million since its launch. Annually, between 900 and 1,500 people in the United States are newly diagnosed with a desmoid tumor. The European market is also opening up; the European Commission granted marketing authorization for OGSIVEO in August 2025, making it the first and only approved therapy in the European Union (EU) for this condition.

Adult and Pediatric Patients with Symptomatic NF1-PN Not Amenable to Complete Resection

This segment is targeted by GOMEKLI (mirdametinib), which gained FDA approval in February 2025, making it the first and only medicine approved for both adults and children with symptomatic NF1-PN not amenable to complete resection. In the U.S., there are an estimated 40,000 people living with NF1-PN. Critically, adults make up about 75% of this patient population, a group previously managed only with off-label therapies or surgery. The pivotal Phase 2b ReNeu trial that supported this approval enrolled 114 patients in total: 58 adults and 56 pediatric patients aged 2 years and older.

Here's a quick math on the target populations for the two commercial assets:

Indication	Drug	U.S. Patient Estimate	Key Demographic Split	2024 Revenue (USD)
Progressing Desmoid Tumors	OGSIVEO	900 to 1,500 new diagnoses annually	Adults requiring systemic treatment	$172.0 million (FY 2024 Net Product Revenue)
Symptomatic NF1-PN	GOMEKLI	Approximately 40,000 total patients	Adults represent approximately 75%	N/A (Approved Feb 2025)

Oncologists and Rare Tumor Specialists Prescribing OGSIVEO and GOMEKLI

The adoption curve for these specialized therapies depends heavily on key prescribers. For GOMEKLI, initial commercial efforts focused on building relationships within specialized centers. Management indicated an initial focus on approximately 70 NFCN (Neurofibromatosis Clinical Network) centers and other key sites in the U.S. as of January 2025. For OGSIVEO, the launch success was supported by an 'enthusiastic prescriber base' showing a strong preference for the drug early in 2025. These specialists are the gatekeepers to the patient pools.

Academic and Industry Partners for Combination Therapy Trials

SpringWorks Therapeutics, Inc. is actively expanding the utility of its molecules through external collaborations, which broadens the potential customer base beyond the initial rare disease indications. This is particularly true for OGSIVEO (nirogacestat) in oncology settings. The company continues to support several industry and academic collaborator studies evaluating nirogacestat as part of BCMA (B-cell maturation antigen) combination therapy regimens for patients with multiple myeloma.

The key external players involved in clinical development, including those for nirogacestat, include:

• Academic Collaborators like the Children's Oncology Group (COG) for a Phase 2 trial in pediatric desmoid tumors.
• Industry partners for preclinical, Phase 1, and Phase 2 studies involving nirogacestat, such as GSK, Janssen, Pfizer, Regeneron, and AbbVie.
• The planned acquisition by Merck KGaA in April 2025 solidifies a major industry relationship, aligning SWTX's rare tumor portfolio with Merck's broader healthcare strategy.

Finance: draft 13-week cash view by Friday.

SpringWorks Therapeutics, Inc. (SWTX) - Canvas Business Model: Cost Structure

The cost structure for SpringWorks Therapeutics, Inc. is heavily weighted toward operating expenses supporting commercialization and pipeline progression as of late 2025. The primary cost drivers are Selling, General, and Administrative (SG&A) and Research and Development (R&D) activities.

Expense Category	Q1 2025 Amount (Millions USD)
Selling, General, and Administrative (SG&A)	$76.5
Research and Development (R&D)	$49.6
Milestone Payment to Pfizer	$6.0

High Selling, General, and Administrative (SG&A) expenses totaled $76.5 million in Q1 2025. This increase was driven by commercial launches.

Significant Research and Development (R&D) expenses were $49.6 million in Q1 2025, focused on pipeline advancement.

The company incurred costs associated with manufacturing and supply chain for two commercial products.

Milestone payments to partners included a $6.0 million payment to Pfizer in Q1 2025.

Costs related to global regulatory filings and post-marketing commitments are also a component of the structure.

Additional financial context for Q1 2025 operating costs includes:

• Net loss of $83.2 million.
• Net cash used in operating activities of $68.8 million.
• Cash, cash equivalents, and marketable securities balance of $382.7 million as of March 31, 2025.

The commercial success of the two products contributed to revenue, but also to the operating expense base. OGSIVEO generated $44.1 million in Q1 2025 revenue, and GOMEKLI contributed $4.9 million following its U.S. launch in February 2025.

Future R&D commitments include an expected IND filing for SW-3431 by the end of 2025.

Finance: draft 13-week cash view by Friday.

SpringWorks Therapeutics, Inc. (SWTX) - Canvas Business Model: Revenue Streams

You're looking at the top-line drivers for SpringWorks Therapeutics, Inc. as of late 2025. The revenue streams are heavily weighted toward the commercial success of their two approved products, supplemented by potential non-recurring events like voucher monetization and contractual milestones.

The immediate, tangible revenue comes from product sales, which showed significant growth early in the year. For the first quarter of 2025, the combined net product revenue hit $49.1 million.

Here's the quick math on the product revenue breakdown for Q1 2025:

Product	Q1 2025 Net Product Revenue
OGSIVEO (nirogacestat)	$44.1 million
GOMEKLI (mirdametinib)	$4.9 million

Looking ahead, the market consensus for the full fiscal year 2025 revenue is set at approximately $330.84 million. That figure incorporates the expected ramp-up for both OGSIVEO and the initial contribution from GOMEKLI, which received its FDA approval in February 2025.

Beyond product sales, SpringWorks Therapeutics has other important, albeit less predictable, revenue components:

• Milestone payments and royalties from licensing agreements, such as the initial arrangement with Pfizer, which entitles Pfizer to undisclosed payments tied to clinical development milestones and royalties on sales of approved products.
• Potential revenue from the monetization of the Rare Pediatric Disease Priority Review Voucher (PRV).
• Other potential milestone payments from out-licensed assets, like the FAAH inhibitor program, which could yield up to $375.0 million in potential milestone payments plus incremental tiered royalties in the mid- to high-single digit percentages on future net sales of that specific asset.

The Rare Pediatric Disease Priority Review Voucher (PRV) is a key non-recurring asset. SpringWorks Therapeutics received this voucher following the February 11, 2025, FDA approval of GOMEKLI (mirdametinib) for symptomatic NF1-PN. While the program itself expired at the end of 2024, GOMEKLI's approval qualified the company to receive one. These vouchers are highly valuable; for instance, recent comparable sales have been reported in the range of $150 million to $155 million, representing a significant, one-time cash infusion opportunity if SpringWorks Therapeutics chooses to sell it rather than redeem it for an expedited review of a future product.

So, you've got the core product sales, the full-year projection, and the potential upside from contractual milestones and the PRV. Finance: draft 13-week cash view by Friday.